Results 1 to 10 of about 12,743 (165)

Pyrazinamide resistance in rifampicin discordant tuberculosis. [PDF]

open access: yesPLoS ONE, 2022
IntroductionMycobacterium tuberculosis strains with phenotypically susceptible rpoB mutations (rifampicin discordant) have emerged following implementation of rapid molecular drug resistance testing for tuberculosis. Whilst rifampicin resistance is known
Nomonde Ritta Mvelase   +3 more
doaj   +5 more sources

Molecular analysis of pyrazinamide resistance in Mycobacterium tuberculosis in Vietnam highlights the high rate of pyrazinamide resistance-associated mutations in clinical isolatesPncA mutations and PZA resistance in M. tuberculosis in Vietnam [PDF]

open access: yesEmerging Microbes and Infections, 2017
Pyrazinamide (PZA) is a key antibiotic in current anti-tuberculosis regimens. Although the WHO has stressed the urgent need to obtain data on PZA resistance, in high tuberculosis burden countries, little is known about the level of PZA resistance, the ...
Nguyen Quang Huy   +9 more
doaj   +7 more sources

Association between overexpression of efflux pumps genes Rv0191 and Rv3008 and pyrazinamide resistance in multidrug-resistant Mycobacterium tuberculosis: a multi-center study [PDF]

open access: yesBMC Infectious Diseases
Background Pyrazinamide is a drug that helps shorten the duration of tuberculosis treatment. Mutations in the pncA are the most common mechanism of pyrazinamide resistance in M. tuberculosis.
Mohammad Hashemzadeh   +4 more
doaj   +2 more sources

Prevalence and Clinical Implications of Pyrazinamide Resistance in Newly Diagnosed TB Patients in Uganda [PDF]

open access: yesInfection and Drug Resistance
Christopher Ndawula, Nalumaga Pauline Petra, Fredrickson B Wasswa, Joel Bazira Department of Microbiology, Mbarara University of Science and Technology, Mbarara, 1410, UgandaCorrespondence: Joel Bazira, Email jbazira@must.ac.ugBackground: Globally, 10.8 ...
Ndawula C, Petra NP, Wasswa FB, Bazira J
doaj   +2 more sources

Predicting pyrazinamide resistance in Mycobacterium tuberculosis using a graph convolutional network [PDF]

open access: yesBMC Microbiology
Background Pyrazinamide is an important first-line antibiotic for treating tuberculosis, with resistance primarily driven by mutations in the pncA gene. Traditional machine learning models are able to predict pyrazinamide resistance with some success but
Dylan Dissanayake   +4 more
doaj   +2 more sources

Underestimated pyrazinamide resistance may compromise outcomes of pyrazinamide containing regimens for treatment of drug susceptible and multi-drug-resistant tuberculosis in Tanzania [PDF]

open access: yesBMC Infectious Diseases, 2019
Background Tuberculosis (TB) is the leading cause of death from an infectious disease and the roll-out of rapid molecular diagnostics for rifampin resistance has resulted in a steady rise in the number of patients with multidrug-resistant (MDR)-TB ...
Saumu Pazia Juma   +9 more
doaj   +2 more sources

Pyrazinamide resistance and mutations in pncA among isolates of Mycobacterium tuberculosis from Khyber Pakhtunkhwa, Pakistan [PDF]

open access: yesBMC Infectious Diseases, 2019
Background Pyrazinamide (PZA) is an important component of first-line drugs because of its distinctive capability to kill subpopulations of persistent Mycobacterium tuberculosis (MTB).
Muhammad Tahir khan   +6 more
doaj   +2 more sources

Mycobacterium tuberculosis Pyrazinamide Resistance Determinants: a Multicenter Study [PDF]

open access: yesmBio, 2014
Pyrazinamide (PZA) is a prodrug that is converted to pyrazinoic acid by the enzyme pyrazinamidase, encoded by the pncA gene in Mycobacterium tuberculosis.
Paolo Miotto   +17 more
doaj   +2 more sources

Isoniazid resistance profile and associated levofloxacin and pyrazinamide resistance in rifampicin resistant and sensitive isolates/from pulmonary and extrapulmonary tuberculosis patients in Pakistan: A laboratory based surveillance study 2015-19. [PDF]

open access: yesPLoS ONE, 2020
BackgroundPakistan is among top five high burden countries for tuberculosis and drug resistant TB. Among rifampicin sensitive new pulmonary TB (PTB), prevalence of isoniazid resistance is 8.3% (95%CI: 7.0-10.7) and resistance to fluoroquinolone is higher
Sabira Tahseen   +6 more
doaj   +2 more sources

Home - About - Disclaimer - Privacy